$52.9 M

MBRX Mkt cap, 10-Jun-2019
Moleculin Biotech Net income (FY, 2018)-11.9 M
Moleculin Biotech EBIT (FY, 2018)-15 M
Moleculin Biotech Cash, 31-Dec-20187.1 M

Moleculin Biotech Income Statement

Annual

USDFY, 2016FY, 2017FY, 2018

R&D expense

1.5m4.5m9.7m

General and administrative expense

2.4m4.1m5.2m

Operating expense total

3.9m8.7m15.0m

Depreciation and amortization

6.2k18.0k68.0k

EBIT

(3.9m)(8.7m)(15.0m)

Interest expense

43.2k4.0k

Interest income

4.0k

Net Income

(3.9m)(9.8m)(11.9m)

Quarterly

USDQ2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018

R&D expense

104.8k496.7k683.0k515.0k1.1m1.2m5.5m

General and administrative expense

618.0k924.0k848.0k800.0k1.3m1.4m2.6m

Operating expense total

723.5k1.4m1.5m1.3m2.4m2.6m8.1m

Depreciation and amortization

652.0977.04.0k5.0k5.0k8.0k15.0k

EBIT

(723.5k)(1.4m)(1.5m)(1.3m)(2.4m)(2.6m)(8.1m)

Interest expense

15.2k10.4k1.0k1.0k1.0k4.0k

Interest income

1.0k4.0k

Net Income

(738.7k)(1.4m)(329.0k)(3.4m)(2.9m)(1.9m)(7.1m)

Moleculin Biotech Balance Sheet

Annual

USDFY, 2016FY, 2017FY, 2018

Cash

5.0m7.7m7.1m

Current Assets

5.2m8.3m8.0m

Total Assets

16.4m19.5m19.6m

Accounts Payable

1.0m810.0k1.2m

Current Liabilities

1.3m2.2m3.9m

Long-term debt

296.4k

Total Debt

296.4k

Total Liabilities

1.4m2.4m5.3m

Additional Paid-in Capital

19.6m31.6m40.6m

Retained Earnings

(4.7m)(14.5m)(26.4m)

Total Equity

15.0m17.1m14.3m

Debt to Equity Ratio

0 x

Debt to Assets Ratio

0 x

Financial Leverage

1.1 x1.1 x1.4 x

Moleculin Biotech Cash Flow

Annual

USDFY, 2016FY, 2017FY, 2018

Net Income

(3.9m)(9.8m)(11.9m)

Depreciation and Amortization

6.2k18.0k68.0k

Accounts Payable

(41.1k)411.0k436.0k

Cash From Operating Activities

(3.8m)(7.3m)(12.2m)

Purchases of PP&E

(28.0k)(417.0k)

Cash From Investing Activities

(121.1k)(28.0k)(417.0k)

Long-term Borrowings

(469.9k)

Cash From Financing Activities

8.9m10.1m12.0m

Interest Paid

4.6k3.0k5.0k

Quarterly

USDQ3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018

Net Income

(2.5m)(329.0k)(3.8m)(6.6m)(1.9m)(7.1m)

Depreciation and Amortization

1.6k4.0k8.0k13.0k8.0k15.0k

Accounts Payable

(146.8k)49.0k(160.0k)285.0k(239.0k)866.0k

Cash From Operating Activities

(2.6m)(1.4m)(3.3m)(4.9m)(2.8m)(6.3m)

Purchases of PP&E

(4.0k)(12.0k)(8.0k)(8.0k)

Cash From Investing Activities

(109.8k)(4.0k)(12.0k)(8.0k)(8.0k)

Long-term Borrowings

(469.9k)

Cash From Financing Activities

8.9m5.3m7.6m8.7m8.2m10.3m

Interest Paid

48.0k2.0k1.0k1.0k

Income Taxes Paid

5.0k15.0k

Moleculin Biotech Ratios

USDY, 2018

Financial Leverage

1.4 x